Cardiovascular · Blood Pressure · Athletic Performance

ACE I/D: The Blood Pressure Gene That Also Determines Your Athletic Ceiling

The ACE gene controls a single enzyme that regulates your blood pressure, fluid balance, and vascular response to exercise. Its insertion/deletion polymorphism is simultaneously one of the most studied variants in sports medicine — elite endurance athletes are disproportionately II carriers — and one of the most clinically relevant in cardiovascular risk. The same biology that limits your VO2 max ceiling also affects your hypertension risk and how aggressively you respond to ACE inhibitor medications.

Published Feb 26, 2026·7 min read·6 peer-reviewed citations

Key Findings at a Glance

→ACE encodes angiotensin-converting enzyme, which converts angiotensin I to angiotensin II — the primary vasoconstrictor that raises blood pressure
→The I/D polymorphism is a 287-base-pair insertion or deletion in intron 16 — the D allele produces ~65% more circulating ACE enzyme than the I allele
→DD genotype: higher ACE activity, greater cardiovascular risk, better explosive power response; II genotype: lower ACE activity, endurance advantage, lower hypertension risk
→Elite endurance athletes (marathon runners, rowers, mountaineers) show 2-3× overrepresentation of the I allele versus general population
→DD carriers on ACE inhibitors respond more dramatically — and may need lower doses to achieve the same blood pressure control
→ACE I/D interacts with PPAR-γ (metabolic risk compound), TNF-α (inflammatory amplification), and VDR (blood pressure via renin-angiotensin)

What ACE Actually Does

Angiotensin-converting enzyme (ACE) is the central enzyme of the renin-angiotensin-aldosterone system (RAAS) — the hormonal cascade that controls blood pressure, blood volume, and electrolyte balance. Its primary job is to cleave angiotensin I (a relatively inactive peptide) into angiotensin II (the potent vasoconstrictor).

Angiotensin II does several things simultaneously: it causes blood vessels to constrict (raising pressure), signals the kidneys to retain sodium and water (raising volume), and stimulates aldosterone release (further raising sodium retention). Together these effects make ACE one of the most powerful determinants of baseline blood pressure.

ACE also degrades bradykinin — a vasodilator that lowers blood pressure and protects vascular endothelium. So high ACE activity means two things at once: more angiotensin II (pressure up) and less bradykinin (vasodilation suppressed). This dual mechanism is why ACE inhibitors work so well as antihypertensives — they block both pathways simultaneously.

In the context of exercise, ACE activity also regulates muscle blood flow and oxygen delivery efficiency. Lower ACE activity (the I allele) preserves more bradykinin, which improves vasodilation in working muscles and enhances oxygen extraction — a significant advantage in sustained aerobic effort.

Renin-Angiotensin System

Angiotensinogen

→ renin

Liver protein cleaved by kidney renin

Angiotensin I

→ ACE

Inactive precursor converted by ACE in lung capillaries

Angiotensin II

→ AT1 receptor

Potent vasoconstriction + aldosterone release + sodium retention

Bradykinin

← ACE degrades

Vasodilator; ACE destroys it — DD carriers lose more bradykinin protection

The I/D Polymorphism: What Changes

The ACE insertion/deletion (I/D) polymorphism is technically not an SNP — it's a 287-base-pair Alu repeat sequence in intron 16 of the ACE gene. The D allele lacks this sequence; the I allele contains it. This is a structural variant, not a point mutation.

The functional consequence is substantial: plasma ACE enzyme levels differ markedly by genotype. Rigat et al. (1990) established the foundational finding: the D allele is associated with significantly higher circulating ACE, with DD homozygotes showing roughly twice the ACE activity of II homozygotes, and ID heterozygotes falling in between. Later studies refined this to a ~65% ACE activity increase per D allele copy.

Population frequency varies substantially by ancestry. In European populations, allele frequencies run approximately 45-50% D and 50-55% I, making it roughly co-dominant. East Asian populations show higher I allele frequency (~65-70% I). West African populations also trend toward higher I frequency. The DD genotype is present in roughly 25% of Europeans, ID in ~50%, II in ~25%.

Importantly, because this is an indel (insertion/deletion) rather than a substitution, it is not captured by standard SNP arrays used by 23andMe and AncestryDNA. Some services use the rs4341 or rs4646994 proxies, which are in near-complete linkage disequilibrium with the I/D variant.

What Each Genotype Means

High ACE Activity (~25% of Europeans)

You have the highest circulating ACE enzyme levels of any genotype — roughly 2× the enzyme activity of II carriers. This means higher baseline angiotensin II production, lower bradykinin preservation, and a vascular system that trends toward higher tone and pressure.

→Cardiovascular: Higher risk of hypertension, left ventricular hypertrophy, and adverse outcomes following MI. Multiple studies show DD associated with 1.3-1.6× elevated risk of coronary artery disease, though absolute risk depends heavily on lifestyle.

→Athletic profile: Better explosive power and strength response to training; disadvantaged in sustained aerobic events. Power athletes (sprinters, weightlifters) show slight D allele enrichment.

→Medication response: Respond most dramatically to ACE inhibitors — significant blood pressure reduction at standard doses. May be prone to ACE inhibitor-induced cough (bradykinin accumulation when ACE is blocked).

→Kidney risk: Higher ACE activity accelerates progression of diabetic nephropathy and other proteinuric conditions — ACE inhibition is particularly protective for DD diabetics.

Protocol focus: Prioritize aerobic exercise for vascular health, sodium restriction, omega-3 supplementation for vascular inflammation. If hypertensive, ACE inhibitors or ARBs are genotype-appropriate first-line choices.

Intermediate ACE Activity (~50% of Europeans)

Heterozygous carriers fall between the two extremes on essentially every measured parameter — ACE levels, blood pressure risk, VO2 max potential, and medication sensitivity. This is the most common genotype and the most phenotypically flexible.

→Risk profile: Intermediate cardiovascular risk — elevated above II but substantially below DD. ID individuals benefit from the same lifestyle interventions as DD but with more metabolic flexibility.

→Athletic potential: Genuinely competitive across both endurance and power disciplines. Elite athletes at the extremes tend to be II (endurance) or DD (power), but world-class ID carriers exist in both.

→Medication: Standard dosing guidelines apply; individual titration needed.

Low ACE Activity (~25% of Europeans)

The insertion allele produces significantly lower circulating ACE. Less angiotensin II production means lower baseline vascular tone and better bradykinin preservation — the vasodilator that improves muscle oxygen delivery during sustained effort.

→Endurance advantage: The most consistent finding in ACE sports genetics: elite endurance athletes are 2-3× more likely to be II carriers than the general population. Studies of marathon runners, Olympic rowers, elite cyclists, and high-altitude mountaineers consistently replicate this pattern.

→Cardiovascular protection: Lower lifetime hypertension risk, lower ACE-driven vascular remodeling. Some studies show lower MI mortality risk in II carriers.

→Medication: Less responsive to ACE inhibitors (less enzyme to inhibit); ARBs may be more effective as the primary intervention. Lower cough risk with ACE inhibitors.

→Altitude: Exceptional altitude performance. The ACE I allele is significantly overrepresented in Sherpa populations and mountaineers who complete high-altitude ascents without supplemental oxygen.

Protocol focus: Your cardiovascular risk floor is lower — don't waste the advantage. Sustained aerobic training amplifies the II genotype's vascular efficiency. You can likely tolerate higher training volumes with less hypertension signal.

The Sports Genetics Story

ACE I/D is one of the most replicated variants in sports genetics — and also one of the most frequently overhyped. The findings are real, but they operate at the population level, not the individual destiny level.

Montgomery et al. (1998) published the foundational study: among British army recruits undergoing 11 weeks of physical training, II genotype individuals showed significantly greater VO2 max improvement than DD individuals. This wasn't about baseline fitness — it was about the genetic ceiling on aerobic training response.

Subsequent studies on elite populations sharpened the picture. Gayagay et al. (1998) found that elite Australian rowers — all Olympic-level athletes — showed significant I allele enrichment versus recreational athletes. Williams et al. (2000) found similar patterns in British endurance athletes. Studies of Himalayan mountaineers (Tsianos et al., 2005) found dramatic I allele overrepresentation among those who completed extreme altitude ascents.

The mechanism is understood: lower ACE activity → more bradykinin → enhanced muscle vasodilation during sustained effort → better oxygen extraction at high workloads → higher effective VO2 max. This is a capillary-level efficiency advantage, not a heart-size advantage.

ACE Genotype Across Athletic Contexts

Context	DD	ID	II
Marathon / Triathlon	Disadvantaged	Competitive	Overrepresented at elite level
Sprint / Power events	Slight advantage	Competitive	Slight disadvantage
Resistance training gains	Higher hypertrophy response	Average	Lower acute strength response
High-altitude performance	Significantly impaired	Moderate	Exceptional (Sherpa pattern)
VO2 max training response	Lower ceiling	Intermediate	Highest ceiling
Rowing (Olympic level)	Underrepresented	Present	Overrepresented

The key caveat: these are population-level patterns with substantial overlap. A DD individual with exceptional training, mechanics, and mental fortitude can outperform most II individuals. The variant shifts the distribution of outcomes, not individual destiny. What it does determine is the relative ROI on training investment — II individuals get more VO2 max improvement per unit of endurance training.

Cardiovascular Risk: What the Evidence Actually Shows

The cardiovascular literature on ACE I/D is large, sometimes contradictory, and often context-dependent. The strongest and most replicated findings:

Hypertension Risk

DD carriers show modestly elevated hypertension risk across multiple cohort studies. The mechanism is direct: higher ACE → more angiotensin II → higher baseline vascular tone. The effect size is real but not deterministic — a DD carrier with optimal lifestyle (low sodium, regular exercise, healthy weight) can have lower blood pressure than an II carrier living poorly. The variant shifts the setpoint, not the outcome.

Coronary Artery Disease and MI

Rigat et al.'s original 1990 paper and subsequent meta-analyses suggest DD is associated with elevated MI risk (odds ratios in the 1.3-1.6 range in early studies). However, large prospective cohorts, including the ECTIM study and Physicians' Health Study, produced mixed results. Current consensus: ACE I/D contributes to CAD risk but with modest individual-level predictive value. It is a useful component of polygenic risk rather than a standalone marker.

Diabetic Nephropathy

This is the strongest clinical signal. DD genotype significantly accelerates progression of diabetic kidney disease — through angiotensin II's direct effects on glomerular pressure and proteinuria. ACE inhibition is particularly protective for DD diabetics with early nephropathy. This is one of the few ACE I/D findings with direct clinical management implications.

Stroke

DD shows modest association with ischemic stroke risk, consistent with the hypertension and vascular remodeling mechanisms. The effect is clearest in populations with high baseline hypertension prevalence.

Evidence-Based Interventions by Genotype

Intervention	DD	ID	II
Sodium restriction	Critical DD is sodium-sensitive; each gram reduction has outsized BP impact	Important	Beneficial Less sensitive to sodium intake
Omega-3 (EPA/DHA)	Priority Reduces angiotensin II signaling, vascular inflammation; 2-3g EPA+DHA/day	Beneficial 1-2g EPA+DHA	General benefit Less cardiovascular urgency
Magnesium	Priority Natural calcium channel blocker; 300-400mg glycinate/malate; ACE antagonism mechanism	Beneficial	Beneficial
Aerobic exercise	Non-negotiable Physically lowers ACE activity; 150+ min/week moderate cardio is the most powerful DD intervention	Important	Amplifying Aerobic training has greater ROI for II genotype; invest heavily here
CoQ10	Consider Supports endothelial function; 100-200mg/day; especially relevant if on statins	Optional	Optional
Beet/nitrate supplementation	Moderate benefit Dietary nitrate → NO → vasodilation; partially compensates for reduced bradykinin	Beneficial	Performance amplifier Stack with lower ACE baseline for cumulative vasodilation advantage
ACE inhibitors (Rx)	Highly responsive Dramatic BP reduction at standard doses; first-line choice if hypertensive DD	Standard response	Lower response ARBs may be more effective; discuss with physician

Gene Interactions That Matter

ACE I/D doesn't operate in isolation. Several interactions are clinically meaningful:

PPAR-γ

Metabolic Risk Compound

DD + Pro/Pro (high PPAR-γ): the cardiovascular risk combination. Higher ACE activity raises blood pressure; higher PPAR-γ activity increases visceral fat accumulation and insulin resistance. Together, these two genotypes push the classic metabolic syndrome phenotype. Both respond to aerobic exercise and dietary fat modification. See PPAR-γ article →

TNF-α

Vascular Inflammation Amplifier

DD + high TNF-α activity (AA genotype at rs1800629): angiotensin II directly upregulates TNF-α expression, and TNF-α independently damages endothelium and promotes atherosclerosis. This compound produces accelerated vascular aging. Both respond to omega-3 and exercise. See TNF-α article →

VDR

Blood Pressure via Renin Regulation

Vitamin D suppresses renin production — reducing the upstream input that drives ACE activity. DD carriers with VDR variants (particularly Fok1 ff) face a double pressure on the RAAS system: high ACE AND vitamin D resistance reducing renin suppression. Vitamin D optimization is particularly high-priority for this combination. See VDR article →

MTHFR

Homocysteine-Endothelial Compound

Elevated homocysteine (from impaired methylation in MTHFR C677T carriers) independently damages vascular endothelium and accelerates atherosclerosis. DD carriers with MTHFR C677T TT genotype face both ACE-driven vascular tone elevation and homocysteine-driven endothelial injury. Methylated B vitamin supplementation is particularly important for this combination. See MTHFR article →

The Differential Susceptibility Frame

The ACE I/D variant fits the differential susceptibility model particularly well (Belsky et al., 2009) — but with an important twist. Unlike SLC6A4 or BDNF (where the “risk” allele is more reactive to environment in both directions), ACE I/D shows asymmetric plasticity.

The DD genotype is highly responsive to environmental inputs — sodium intake, exercise level, stress, body weight — in a way that II genotypes are not. A DD carrier living a low-sodium, high-activity life can have blood pressure indistinguishable from II carriers. A DD carrier living a high-sodium, sedentary life will accumulate cardiovascular risk faster than any other genotype.

Meanwhile, II genotype individuals accrue exceptional benefits from endurance training investment in a way DD carriers cannot fully replicate — not because II carriers “need” exercise more, but because the biological machinery for aerobic adaptation is more responsive.

The practical frame: DD is not a “bad” genotype — it's a high-sensitivity genotype that expresses risk under poor conditions and neutralizes risk under optimal ones. II is an endurance-optimized genotype. Both carry real phenotypic significance only in interaction with how you live.

Monitoring What Matters

For DD carriers especially, these markers track ACE-relevant cardiovascular risk most directly:

Blood pressure (systolic/diastolic)

Below 120/80; for DD, trend matters as much as single reading

Monthly self-monitoring; quarterly clinical

hsCRP

Below 1.0 mg/L; DD + high TNF-α compounds vascular inflammation

Every 6-12 months

Homocysteine

Below 10 µmol/L (especially important for DD + MTHFR compound)

Annually

eGFR and microalbuminuria

eGFR stable; no microalbuminuria — especially critical for DD diabetics

Annually; every 6 months if diabetic

Fasting insulin / HOMA-IR

HOMA-IR below 2.0; DD + high PPAR-γ compound needs metabolic monitoring

Annually

Omega-3 index

Above 8% EPA+DHA in red blood cell membranes

Annually or when adjusting supplementation

Research Citations

Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F (1990). An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. Journal of Clinical Investigation, 86(4), 1343–1346.

Montgomery HE, Marshall R, Hemingway H, et al. (1998). Human gene for physical performance. Nature, 393(6682), 221–222.

Gayagay G, Yu B, Hambly B, et al. (1998). Elite endurance athletes and the ACE I allele — the role of genes in athletic performance. Human Genetics, 103(1), 48–50.

Williams AG, Rayson MP, Jubb M, et al. (2000). The ACE gene and muscle performance. Nature, 403(6770), 614.

Tsianos GI, Eleftheriou KI, Hawe E, et al. (2005). Performance at altitude and angiotensin I-converting enzyme genotype. European Journal of Applied Physiology, 93(5–6), 630–633.

Belsky J, Jonassaint C, Pluess M, Stanton M, Brummett B, Williams R (2009). Vulnerability genes or plasticity genes?. Molecular Psychiatry, 14(8), 746–754.